About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Dallas | 17,468 Studies Near You | Clareo Health

Clinical Trials LocationsDallas

Clinical Trials in Dallas

Discover 17,468 clinical trials near Dallas, Texas. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 16901-16920 of 17,468 trials

COMPLETEDPhase 1< 1 mile

ARQ 197 in Subjects With Metastatic Solid Tumors

NCT00302172

To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197.

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)78 participantsStarted Jan 2006

Santa Monica, California, United States • Cleveland, Ohio, United States • Dallas, Texas, United States

COMPLETEDPhase 3< 1 mile

A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels

NCT00225615

The primary objective of this trial is to evaluate the safety and tolerability of long-term Phenoptin treatment in subjects with PKU.

Phenylketonurias

BioMarin Pharmaceutical100 participantsStarted Nov 2005

Los Angeles, California, United States • Oakland, California, United States • Sacramento, California, United States +11 more locations

Find Trials by Condition in Dallas

Breast Cancerin Dallas Lung Cancerin Dallas Prostate Cancerin Dallas Colorectal Cancerin Dallas Melanomain Dallas Leukemiain Dallas Lymphomain Dallas Pancreatic Cancerin Dallas Ovarian Cancerin Dallas Brain Cancerin Dallas Diabetesin Dallas

Data from ClinicalTrials.govTerms

COMPLETED< 1 mile

Comparison of Prosthetic Femoropopliteal Bypass Versus Viabahn Endoprosthesis for Treatment of Symptomatic Femoral Artery Occlusion

NCT00962897

A retrospective review with four year followup on patients that had previously been enrolled in a study to evaluate blockages in the lower legs. The study looked at patients that had undergone a bypass of the leg from the groin to the knee area with an incision in each area using general anesthesia. These patients were compared to others who had undergone treatment with balloon dilatation and stents in the arteries in the thighs with only numbing medicine. The study was completed two years ago and was initially designed to look at outcomes at 24 months. Now the investigators are trying to go back and look at outcomes of these patients' treatment at 4 years by simply reviewing their records.

AtherosclerosisLower Extremity IschemiaClaudication+1 more

Texas Vascular Associates100 participantsStarted Sep 2003

Dallas, Texas, United States

COMPLETEDPhase 2/3< 1 mile

A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects

NCT00134199

To evaluate the effect of 6-month administration of CP-945,598 on: * weight loss and waist circumference, * blood pressure, cholesterol, glucose * other biochemical variables like insulin, leptin, ghrelin, adiponectin, PAI 1, TNF-Î± and hsCRP * the relationship between the concentration of the drug on the blood and the above parameters * physical and psychosocial functioning, weight related symptoms, treatment satisfaction, appetite/hunger/satiety/craving and mood, anxiety, anhedonia and depression

Pfizer282 participantsStarted Mar 2005

Clearwater, Florida, United States • Kissimmee, Florida, United States • Orlando, Florida, United States +12 more locations

UNKNOWNPhase 2< 1 mile

Efficacy and Safety Study of SLC022 in Treating Pain Associated With Post Herpetic Neuralgia

NCT00813826

The purpose of this study is to evaluate the efficacy and safety of SLC022 in treating pain associated with post-herpetic neuralgia (PHN) in recently diagnosed patients.

Postherpetic Neuralgia

Solace Pharmaceuticals204 participantsStarted Jan 2009

Sierra Vista, Arizona, United States • Mission Viejo, California, United States • Orlando, Florida, United States +16 more locations

COMPLETEDPhase 1/2< 1 mile

Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects

NCT00126724

The 13G01 clinical trial is a Phase I/II dose escalation study designed to be conducted in adults with inflammatory arthritis who have persistent moderate or severe swelling in one or more joints, without a disease severe enough to warrant a change in regimen for the next three months. The study will permit subjects who are concurrently on anti-tumor necrosis factor (TNF)-alpha antagonists. For subjects on disease modifying antirheumatic drugs (DMARDs), a stable regimen for inflammatory arthritis for the previous three months, with no changes in doses in the four weeks prior to screening will be required. The primary objectives are: 1. to evaluate the safety of intra-articular administration of tgAAC94 in subjects currently taking TNF-alpha antagonists, and 2. to evaluate the safety of repeat intra-articular administration of tgAAC94 (gene therapy vector).

Arthritis, RheumatoidArthritis, PsoriaticAnkylosing Spondylitis

Targeted Genetics Corporation120 participantsStarted Aug 2005

Glendale, Arizona, United States • Tuscon, Arizona, United States • Palm Desert, California, United States +19 more locations

COMPLETEDPhase 2< 1 mile

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

NCT00403286

The purpose of the study is to determine the appropriate dose of fluticasone propionate/formoterol fumarate that is closest to Advair Diskus (fluticasone propionate/salmeterol xinafoate using pulmonary function, safety, and levels of study drug in blood plasma in patients with chronic obstructive pulmonary disease.

Chronic Obstructive Pulmonary Disease

Dey457 participantsStarted Nov 2006

Birmingham, Alabama, United States • Jasper, Alabama, United States • Phoenix, Arizona, United States +46 more locations

COMPLETEDPhase 213 miles

A Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension

NCT00325962

The purpose of this study is to determine whether 6R-BH4 (sapropterin dihydrochloride) is safe and effective in the treatment of poorly controlled hypertension in the presence or absence of type 2 diabetes.

BioMarin Pharmaceutical84 participantsStarted May 2006

Hoover, Alabama, United States • Huntsville, Alabama, United States • Mobile, Alabama, United States +21 more locations

COMPLETEDPhase 387 miles

Duloxetine Versus Placebo for Osteoarthritis Knee Pain

NCT00408421

The primary purpose of this study is to determine if duloxetine reduces pain severity in patients with osteoarthritis knee pain.

Osteoarthritis Knee Pain

Eli Lilly and Company231 participantsStarted Nov 2006

Chandler, Arizona, United States • Beverly Hills, California, United States • Northridge, California, United States +24 more locations

COMPLETEDPhase 3182 miles

Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

NCT00334880

The purpose of this study is to evaluate the safety and effectiveness of NRP104 administered as a daily morning dose (30, 50, and 70mg/day) compared to placebo in adults (18-55 years of age inclusive) diagnosed with moderate to severe Attention Deficit Hyperactivity Disorder (ADHD).

Attention Deficit Hyperactivity DisorderAttention Deficit Disorders With HyperactivityAttention Deficit Hyperactivity Disorders

New River Pharmaceuticals420 participantsStarted May 2006

Little Rock, Arkansas, United States • El Centro, California, United States • Irvine, California, United States +45 more locations

COMPLETEDPhase 2190 miles

Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)

NCT00104273

The purpose of this study is to evaluate the safety, tolerability, and efficacy of two dose levels of rasagiline mesylate versus placebo in patients with mild-to-moderate Alzheimer's Disease who are taking Aricept.

DementiaAlzheimer's Disease

Teva Branded Pharmaceutical Products R&D, Inc.376 participantsStarted Aug 2004

Huntsville, Alabama, United States • Huntsville, Alabama, United States • Tucson, Arizona, United States +55 more locations

COMPLETEDPhase 3225 miles

Study Evaluating rFIX; BeneFIX® in Hemophilia B

NCT00093171

The primary objective of this clinical research study is to assess the safety and efficacy of rFIX for a minimum of 6 months in previously treated patients (PTPs) with hemophilia B (FIX:C ≤2%) during standard-of-care treatment (on-demand, prophylaxis, and through major and minor surgical procedures).

Wyeth is now a wholly owned subsidiary of Pfizer23 participants

Los Angeles, California, United States • Aurora, Colorado, United States • Detroit, Michigan, United States +4 more locations

COMPLETED225 miles

Evaluation of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Early and Evolving Acute Kidney Injury

NCT00445809

Some patients who undergo cardiovascular surgery requiring cardiopulmonary bypass will develop a kidney injury following their surgery. The purpose of this study is to take a blood sample from patients before they have this type of surgery and then at nine time points after their surgery to test their plasma for a biomarker called NGAL and compare the NGAL levels to their creatinine levels. We hypothesize that NGAL is an earlier marker for kidney injury than creatinine.

Kidney Failure, Acute

Abbott RDx Cardiometabolic355 participantsStarted Feb 2007

Denver, Colorado, United States • Washington D.C., District of Columbia, United States • Portland, Maine, United States +8 more locations

UNKNOWNPhase 1225 miles

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

NCT00053105

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase I trial to study the effect of combination chemotherapy on the body when treating patients who have relapsed or refractory aggressive non-Hodgkin's lymphoma.

TheradexStarted Feb 2002

Tucson, Arizona, United States • Springdale, Arkansas, United States • Los Angeles, California, United States +4 more locations

TERMINATEDPhase 1341 miles

Multiple Dose Escalation Trial Of PF-04603629 Given To Subjects With Type 2 Diabetes Mellitus

NCT00637338

PF-04603629 is being investigated for the treatment of Type 2 diabetes mellitus (T2DM). Specifically, PF-04603629 is a protein that is a combination of exendin-4 (a glucagon-like peptide-1 (GLP-1) mimetic currently marketed as Byetta®) fused to human transferrin (a naturally occuring protein) in order to increase the concentration of exendin-4 in the blood. The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-04603629 following multiple escalating subcutaneous doses in adult subjects with T2DM.

Diabetes Mellitus, Type 2

Pfizer42 participantsStarted Apr 2008

Phoenix, Arizona, United States • Miami, Florida, United States • Wichita, Kansas, United States +1 more locations

COMPLETEDPhase 2420 miles

A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients

NCT00141661

A 10-week safety and tolerability study of a potential treatment for mild to moderate Alzheimer's disease.

Alzheimer Disease

Pfizer67 participantsStarted Oct 2005

Sun City, Arizona, United States • Fresno, California, United States • San Diego, California, United States +9 more locations

SUSPENDEDPhase 2658 miles

Autologous Incubated Macrophages for Patients With Complete Spinal Cord Injuries

NCT00073853

Autologous Incubated Macrophages (ProCord) is being developed as a therapy for acute, complete spinal cord injury (SCI). The therapy is intended to reverse the loss of motor and sensory function. Following non-CNS tissue injury, macrophages quickly arrive on the scene, where they clean up cell debris, secrete different molecules thus promoting a controlled inflammatory reaction that forms the first phase of the wound healing process. While this process occurs in most tissues, including peripheral nerves, it does not occur in the CNS, where macrophages and other immune cells are relatively rare, and their activities curtailed by a biochemical mechanism known as "immune privilege." In animal studies, it appears that incubated macrophages circumvent the immune privilege, thus supporting the regrowth of axons through the injury site and enabling the recovery of neurological function. The concept derives from the pioneering research of Prof. Michal Schwartz at the Weizmann Institute of Science.

Spinal Cord Injury

Proneuron Biotechnologies61 participantsStarted Sep 2003

Englewood, Colorado, United States • Atlanta, Georgia, United States • Newark, New Jersey, United States +4 more locations

COMPLETEDNA924 miles

Effect of South Beach Diet (SBD™) Using SBD™ Products Compared to a Calorie-Restricted Diet in Women

NCT00932516

The purpose of this study is to examine the effectiveness of the South Beach Diet™ and South Beach Diet™ products compared to a traditional calorie restricted diet.

Mondelēz International, Inc.248 participantsStarted Mar 2007

Northridge, California, United States • Bradenton, Florida, United States • Miami, Florida, United States +1 more locations

COMPLETEDNA924 miles

Effect of South Beach Diet (SBD™) Using SBD™ Products Compared to the American Diabetic Association (ADA) Diabetes Meal Plan on Body Weight and Satiety in Diabetic Women

NCT00931034

The purpose of this study is to examine the effectiveness of the South Beach Diet and products compared to the American Diabetic Association Diabetes Meal Plan.

Type 2 Diabetes Mellitus

Mondelēz International, Inc.120 participantsStarted Mar 2007

Northridge, California, United States • Bradenton, Florida, United States • Miami, Florida, United States +3 more locations

TERMINATEDPhase 21147 miles

REGENESIS (CA): A Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

NCT00663416

Primary objective: To assess the neurological outcome in acute ischemic stroke patients treated with NTx™-265, when compared with patients given a placebo control. Secondary objective: To assess the safety and tolerability of NTx™-265 when given to acute ischemic stroke patients.

Stem Cell Therapeutics Corp.134 participantsStarted Mar 2008

Calgary, Alberta, Canada • Edmonton, Alberta, Canada • Edmonton, Alberta, Canada +23 more locations

PreviousPage 846 of 874Next

Heart Diseasein Dallas